Quantcast
Channel: Endpoints News

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly...

Fresh off a splashy obesity deal, Zealand Pharma is doubling down on its R&D ambitions with a new chief scientific officer. The Copenhagen-based biotech, which is partnered with Roche and...

View Article


China’s biotech market is staging a comeback that US biotech can only wish for

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Buoyed by licensing deals, improving company fundamentals and...

View Article


Veraxa makes a SPAC deal; Illumina discloses layoffs

Plus, news about Innate Pharma, Sanofi, Claris Ventures and Rezolute: A rare SPAC deal: At a time when public markets are challenging for IPOs, a Swiss biotech plans to merge with ...

View Article

Top pharma companies increased lobbying spend at start of 2025

Pfizer, Novartis, Amgen, Eli Lilly and Johnson & Johnson were the top congressional lobbying spenders among the major biopharma companies, as the industry faces a tumultuous environment in which...

View Article

Vaccine makers stand by their investments despite US headwinds

WASHINGTON — Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US that risks diminishing a major market. On a panel at the World...

View Article


Europe 'falling behind' on drug R&D and manufacturing investments:...

AstraZeneca CEO Pascal Soriot called on Europe to step up investments and “protect its health sovereignty" as it falls behind the US on spending. His comments echo calls from other pharma CEOs who are...

View Article

Roche Q1 earnings: CEO warns that tariffs could impact dealmaking

Roche said that its future dealmaking could be impacted by potential tariffs on pharmaceuticals. “If there are questions around tariffs, it will be more difficult to make financial sense of any M&A...

View Article

Sanofi Q1 earnings: Altuviiio closing in on blockbuster status, Dupixent...

Sanofi posted a strong set of first-quarter results Thursday morning, with its recombinant factor drug Altuviiio on track to become a blockbuster drug and its crown jewel Dupixent continuing to draw...

View Article


Merck Q1 earnings: Gardasil sales hit by China market pressure

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China. Gardasil is Merck’s second-biggest product behind its megablockbuster...

View Article


Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche and Sanofi said on Thursday morning they have been running scenarios on how US and other tariffs could potentially impact their respective businesses. However, while Roche has detailed specific...

View Article

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff war and NIH funding cuts. Because of the "substantial" US tariff rates on ...

View Article

Bristol Myers Q1 earnings: Transition continues as drugmaker raises guidance

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning. While overall revenue declined by 6% to $11.2...

View Article

Versant's latest biotech focuses on inflammatory diseases

Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for autoimmune and inflammatory diseases. Granite Bio broke cover on Thursday...

View Article


Avidicure's $50M seed round; Flagship's new AI company that detects disease

Plus, news about Novo Holdings, Bioxodes and Tempus AI: Dutch biotech raises $50M in seed funding: Avidicure, which is developing avidity engineered antibodies for cancer, said it plans to use the...

View Article

Lotte Bio launches ADC services; Ypsomed to focus on self-injection business

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lotte Biologics has launched its ADC services and it has signed its ...

View Article


Bristol Myers CEO signals dealmaking will be a top priority in 2025

Is Bristol Myers Squibb ready to take on big dealmaking again? When CEO Chris Boerner took over in late 2023, Bristol Myers was in a difficult position. Its stock price {$BMY} was down more than ...

View Article

The potential of all-AI labs

Picture this: A chemist, biologist and computer scientist are working together in a lab. But in this case, they’re all AI agents trained on reams of papers and data, working in a virtual lab run ...

View Article


Halozyme launches patent fight over Merck's injectable Keytruda

San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents. The...

View Article

Cassidy urges major reforms to 340B drug discount program

The growing drug discount program for low-income Americans, known as the 340B program, has "transparency and oversight concerns" and needs to be reformed, Sen. Bill Cassidy (R-LA), chair of the Senate...

View Article

Drugmakers prepare for manageable tariff hit to business, earnings

For the drug industry, President Donald Trump's tariffs haven't started to really hurt. At least not yet. On Thursday, several of the world’s largest pharma companies — Merck, Bristol Myers Squibb,...

View Article

Biosimilar launch challenges remain, report finds

As President Donald Trump has sought to speed the development and approval of new biosimilar competition to expensive biologics, only 66% of FDA-approved biosimilars have actually been commercialized,...

View Article


Merck is well-stocked on Keytruda as pharma tariffs loom, CEO says

Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling product from the potential impacts of industry-specific tariffs. Without going...

View Article


Caribou lays off 32% of staff, cuts lupus program

Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market. Caribou said Thursday...

View Article

Gilead's strong HIV business balances out low Covid and cancer drug sales

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...

View Article